Immunotherapy does work inside the brain for melanoma patients whose cancer has spread there, and in a proportion of carefully selected patients, the response can last for years. However, most patients told their melanoma has reached the brain are not immediate candidates for immune treatment. The brain must be made safe first, steroids must be reduced, and eligibility depends on a combination of factors that doctors assess together, not on hope or timing alone.

Why Can't Immunotherapy Be Started Right Away for Brain Melanoma?

When melanoma deposits appear in the brain, they often cause immediate problems. A large deposit pressing on brain tissue, one that has bled, or one causing seizures must be treated locally first, usually with stereotactic radiosurgery, which acts within days. High-dose steroids are also started urgently to control brain swelling. But here is the catch: steroids suppress the very immune cells that immunotherapy is trying to release. A patient on a high ongoing steroid dose is essentially receiving a treatment and its opposite at once.

This is not a permanent barrier. It is a sequencing problem. Once the dangerous deposit is treated locally and the steroid dose is tapered under medical supervision, immunotherapy has a fair chance of working. The steroid dose is often the single factor that decides whether a patient can proceed with immune treatment.

What Are the Eligibility Requirements for Brain Melanoma Immunotherapy?

Eligibility involves multiple factors that doctors read together, not in isolation. A medical oncologist, radiation oncologist, and tumor board must review the brain MRI, biopsy report, current steroid dose, previous treatments, and overall fitness before making a decision.

• Brain Stability: Deposits must be small or causing no symptoms, with no dangerous swelling and no need for a high steroid dose to control them.
• Steroid Management: Patients must be on no steroid or a low dose, since high-dose steroids block the immune response that immunotherapy relies on.
• Immune History: Active autoimmune disease, a transplanted organ, or ongoing immune-suppressing treatment are barriers, as is frailty with poor organ reserve, because the question is not only whether a patient would respond, but whether a serious immune reaction could be survived if one occurred.
• Melanoma Subtype: Acral and mucosal melanomas, which are more common in India and start on the sole of the foot, palm, under a nail, or on internal linings like the mouth or nose, are reported to respond less well to immunotherapy than sun-exposure-driven melanomas.

Patients deserve to know which subtype their biopsy shows, because this affects realistic expectations for treatment response.

How Well Does Immunotherapy Actually Work for Brain Melanoma?

The old assumption that the blood-brain barrier prevents immune treatment from reaching brain tumors has not held up. Immunotherapy does not have to reach the deposit itself. Instead, it acts on immune cells, releasing the brakes that hold them back. Once activated, those immune cells travel into brain tissue and do the work. This is why an untargeted drug molecule might not cross the barrier, but an activated immune cell can.

According to current guidance from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) as of August 2026, measurable shrinkage of brain deposits occurs in roughly half of selected patients given two checkpoint inhibitor drugs together, and in roughly one in five to one in four patients given a single drug. These figures describe trial populations of patients whose brain deposits were small, causing no symptoms, not previously treated, and who were not taking steroids. They represent objective response, meaning measurable shrinkage on a scan, not survival figures or predictions for any one person.

Where immunotherapy does work, the response can be durable. Oncologists deliberately use the phrase "durable response" because the same long follow-up that documents responses lasting years also documents late relapses. That is the honest version of the good news, and it is still genuinely good news: two decades ago there was very little to offer patients in this situation at all.

How to Prepare for Brain Melanoma Immunotherapy

• Treat the Brain Deposit Locally First: If a deposit is causing pressure, bleeding, or seizures, stereotactic radiosurgery or surgery is performed before systemic immunotherapy starts. This removes the immediate threat and allows steroids to be tapered.
• Taper Steroids Under Medical Supervision: High-dose steroids must be reduced gradually under close monitoring. Never reduce a steroid dose on your own. Settling the brain, treating the deposit locally, then tapering the steroid is not a delay; it is what gives immune treatment a fair chance.
• Coordinate Radiation and Immunotherapy: Stereotactic radiosurgery acts on one or a few named deposits within days, controlling pressure and symptoms. Immunotherapy acts over weeks to months across the whole body, including deposits nobody has scanned yet. Most treatment plans use both rather than choosing between them, because they answer different questions.
• Understand That Brain and Body May Move Separately: A deposit in the brain can grow while disease elsewhere is shrinking, or the reverse. This is why the brain is scanned on its own schedule with its own MRI and not assumed to be following the body scan.

The two pathways involved when both checkpoint drugs are used work at different points in the immune response. One acts on the PD-1 pathway, which restrains immune cells at the point where they meet the tumor. The other acts on the CTLA-4 pathway, earlier, where immune cells are first switched on in the lymph nodes. Releasing both is reported to produce more activity inside the skull than releasing one, and also considerably more toxicity.

What Should Patients Know About Realistic Outcomes?

The figures describing immunotherapy response in brain melanoma come with important context. They describe carefully selected trial populations, not all patients with brain melanoma. They are objective-response figures, not survival figures. And they do not predict what will happen in any one person. Reading these numbers with their full context is essential for understanding what immunotherapy might offer.

One practical point that surprises families is that the brain and the rest of the body do not always move together. This is why imaging schedules are coordinated separately for the brain and the body, and why a patient's overall treatment plan must account for the possibility that deposits in different locations may respond differently to the same treatment.

For patients with melanoma that has spread to the brain, immunotherapy represents a genuine advance. But success depends on careful sequencing, realistic eligibility assessment, and a treatment plan that combines local and systemic approaches. The key is not rushing into immunotherapy, but preparing the brain and the body to give immune treatment the best possible chance to work.